Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow Article Swipe
Pieter Langerhorst
,
Somayya Noori
,
Marina Zajec
,
Yolanda B. de Rijke
,
Jolein Gloerich
,
Alain J. van Gool
,
Hélène Caillon
,
Irma Joosten
,
Theo M. Luider
,
Jill Corre
,
Martijn M. VanDuijn
,
Thomas Dejoie
,
Joannes F.M. Jacobs
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1093/clinchem/hvab187
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1093/clinchem/hvab187
Background Minimal residual disease (MRD) status assessed on bone marrow aspirates is a major prognostic biomarker in multiple myeloma (MM). In this study we evaluated blood-based targeted mass spectrometry (MS-MRD) as a sensitive, minimally invasive alternative to measure MM disease activity. Methods Therapy response of 41 MM patients in the IFM-2009 clinical trial (NCT01191060) was assessed with MS-MRD on frozen sera and compared to routine state-of-the-art monoclonal protein (M-protein) diagnostics and next-generation sequencing (NGS-MRD) at 2 time points. Results In all 41 patients we were able to identify clonotypic M-protein-specific peptides and perform serum-based MS-MRD measurements. MS-MRD is significantly more sensitive to detect M-protein compared to either electrophoretic M-protein diagnostics or serum free light chain analysis. The concordance between NGS-MRD and MS-MRD status in 81 paired bone marrow/sera samples was 79%. The 50% progression-free survival (PFS) was identical (49 months) for patients who were either NGS-positive or MS-positive directly after maintenance treatment. The 50% PFS was 69 and 89 months for NGS-negative and MS-negative patients, respectively. The longest 50% PFS (96 months) was observed in patients who were MRD-negative for both methods. MS-MRD relapse during maintenance treatment was significantly correlated to poor PFS (P < 0.0001). Conclusions Our data indicate proof-of-principle that MS-MRD evaluation in blood is a feasible, patient friendly alternative to NGS-MRD assessed on bone marrow. Clinical validation of the prognostic value of MS-MRD and its complementary value in MRD-evaluation of patients with MM is warranted in an independent larger cohort.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/clinchem/hvab187
- https://academic.oup.com/clinchem/article-pdf/67/12/1689/41387849/hvab187.pdf
- OA Status
- hybrid
- Cited By
- 43
- References
- 28
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3206476260
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3206476260Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/clinchem/hvab187Digital Object Identifier
- Title
-
Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone MarrowWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-09-08Full publication date if available
- Authors
-
Pieter Langerhorst, Somayya Noori, Marina Zajec, Yolanda B. de Rijke, Jolein Gloerich, Alain J. van Gool, Hélène Caillon, Irma Joosten, Theo M. Luider, Jill Corre, Martijn M. VanDuijn, Thomas Dejoie, Joannes F.M. JacobsList of authors in order
- Landing page
-
https://doi.org/10.1093/clinchem/hvab187Publisher landing page
- PDF URL
-
https://academic.oup.com/clinchem/article-pdf/67/12/1689/41387849/hvab187.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/clinchem/article-pdf/67/12/1689/41387849/hvab187.pdfDirect OA link when available
- Concepts
-
Minimal residual disease, Multiple myeloma, Bone marrow, Mass spectrometry, Medicine, Pathology, Internal medicine, Chromatography, ChemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
43Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 7, 2024: 14, 2023: 16, 2022: 5, 2021: 1Per-year citation counts (last 5 years)
- References (count)
-
28Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3206476260 |
|---|---|
| doi | https://doi.org/10.1093/clinchem/hvab187 |
| ids.doi | https://doi.org/10.1093/clinchem/hvab187 |
| ids.mag | 3206476260 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/34643690 |
| ids.openalex | https://openalex.org/W3206476260 |
| fwci | 6.68362107 |
| mesh[0].qualifier_ui | Q000378 |
| mesh[0].descriptor_ui | D001853 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | metabolism |
| mesh[0].descriptor_name | Bone Marrow |
| mesh[1].qualifier_ui | Q000379 |
| mesh[1].descriptor_ui | D059014 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | methods |
| mesh[1].descriptor_name | High-Throughput Nucleotide Sequencing |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D006801 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Humans |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D013058 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Mass Spectrometry |
| mesh[4].qualifier_ui | Q000175 |
| mesh[4].descriptor_ui | D009101 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | diagnosis |
| mesh[4].descriptor_name | Multiple Myeloma |
| mesh[5].qualifier_ui | Q000188 |
| mesh[5].descriptor_ui | D009101 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | drug therapy |
| mesh[5].descriptor_name | Multiple Myeloma |
| mesh[6].qualifier_ui | Q000235 |
| mesh[6].descriptor_ui | D009101 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | genetics |
| mesh[6].descriptor_name | Multiple Myeloma |
| mesh[7].qualifier_ui | Q000175 |
| mesh[7].descriptor_ui | D018365 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | diagnosis |
| mesh[7].descriptor_name | Neoplasm, Residual |
| mesh[8].qualifier_ui | Q000378 |
| mesh[8].descriptor_ui | D001853 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | metabolism |
| mesh[8].descriptor_name | Bone Marrow |
| mesh[9].qualifier_ui | Q000379 |
| mesh[9].descriptor_ui | D059014 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | methods |
| mesh[9].descriptor_name | High-Throughput Nucleotide Sequencing |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D006801 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Humans |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D013058 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Mass Spectrometry |
| mesh[12].qualifier_ui | Q000175 |
| mesh[12].descriptor_ui | D009101 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | diagnosis |
| mesh[12].descriptor_name | Multiple Myeloma |
| mesh[13].qualifier_ui | Q000188 |
| mesh[13].descriptor_ui | D009101 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | drug therapy |
| mesh[13].descriptor_name | Multiple Myeloma |
| mesh[14].qualifier_ui | Q000235 |
| mesh[14].descriptor_ui | D009101 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | genetics |
| mesh[14].descriptor_name | Multiple Myeloma |
| mesh[15].qualifier_ui | Q000175 |
| mesh[15].descriptor_ui | D018365 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | diagnosis |
| mesh[15].descriptor_name | Neoplasm, Residual |
| type | article |
| title | Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow |
| awards[0].id | https://openalex.org/G8986789801 |
| awards[0].funder_id | https://openalex.org/F4320322777 |
| awards[0].funder_award_id | 10817 |
| awards[0].funder_display_name | KWF Kankerbestrijding |
| biblio.issue | 12 |
| biblio.volume | 67 |
| biblio.last_page | 1698 |
| biblio.first_page | 1689 |
| grants[0].funder | https://openalex.org/F4320322777 |
| grants[0].award_id | 10817 |
| grants[0].funder_display_name | KWF Kankerbestrijding |
| topics[0].id | https://openalex.org/T10649 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2720 |
| topics[0].subfield.display_name | Hematology |
| topics[0].display_name | Multiple Myeloma Research and Treatments |
| topics[1].id | https://openalex.org/T12534 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9957000017166138 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | Protein Degradation and Inhibitors |
| topics[2].id | https://openalex.org/T12505 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9940999746322632 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Peptidase Inhibition and Analysis |
| funders[0].id | https://openalex.org/F4320322777 |
| funders[0].ror | https://ror.org/0368jnd28 |
| funders[0].display_name | KWF Kankerbestrijding |
| is_xpac | False |
| apc_list.value | 4088 |
| apc_list.currency | USD |
| apc_list.value_usd | 4088 |
| apc_paid.value | 4088 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 4088 |
| concepts[0].id | https://openalex.org/C2779823535 |
| concepts[0].level | 3 |
| concepts[0].score | 0.7478212118148804 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q6865356 |
| concepts[0].display_name | Minimal residual disease |
| concepts[1].id | https://openalex.org/C2776364478 |
| concepts[1].level | 2 |
| concepts[1].score | 0.7373030185699463 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q467635 |
| concepts[1].display_name | Multiple myeloma |
| concepts[2].id | https://openalex.org/C2780007613 |
| concepts[2].level | 2 |
| concepts[2].score | 0.675754964351654 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q546523 |
| concepts[2].display_name | Bone marrow |
| concepts[3].id | https://openalex.org/C162356407 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5461623668670654 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q180809 |
| concepts[3].display_name | Mass spectrometry |
| concepts[4].id | https://openalex.org/C71924100 |
| concepts[4].level | 0 |
| concepts[4].score | 0.5079308152198792 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[4].display_name | Medicine |
| concepts[5].id | https://openalex.org/C142724271 |
| concepts[5].level | 1 |
| concepts[5].score | 0.3462979793548584 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[5].display_name | Pathology |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.2981069087982178 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C43617362 |
| concepts[7].level | 1 |
| concepts[7].score | 0.26483526825904846 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q170050 |
| concepts[7].display_name | Chromatography |
| concepts[8].id | https://openalex.org/C185592680 |
| concepts[8].level | 0 |
| concepts[8].score | 0.210084468126297 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[8].display_name | Chemistry |
| keywords[0].id | https://openalex.org/keywords/minimal-residual-disease |
| keywords[0].score | 0.7478212118148804 |
| keywords[0].display_name | Minimal residual disease |
| keywords[1].id | https://openalex.org/keywords/multiple-myeloma |
| keywords[1].score | 0.7373030185699463 |
| keywords[1].display_name | Multiple myeloma |
| keywords[2].id | https://openalex.org/keywords/bone-marrow |
| keywords[2].score | 0.675754964351654 |
| keywords[2].display_name | Bone marrow |
| keywords[3].id | https://openalex.org/keywords/mass-spectrometry |
| keywords[3].score | 0.5461623668670654 |
| keywords[3].display_name | Mass spectrometry |
| keywords[4].id | https://openalex.org/keywords/medicine |
| keywords[4].score | 0.5079308152198792 |
| keywords[4].display_name | Medicine |
| keywords[5].id | https://openalex.org/keywords/pathology |
| keywords[5].score | 0.3462979793548584 |
| keywords[5].display_name | Pathology |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.2981069087982178 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/chromatography |
| keywords[7].score | 0.26483526825904846 |
| keywords[7].display_name | Chromatography |
| keywords[8].id | https://openalex.org/keywords/chemistry |
| keywords[8].score | 0.210084468126297 |
| keywords[8].display_name | Chemistry |
| language | en |
| locations[0].id | doi:10.1093/clinchem/hvab187 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S139212996 |
| locations[0].source.issn | 0009-9147, 1530-8561 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0009-9147 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Clinical Chemistry |
| locations[0].source.host_organization | https://openalex.org/P4310320272 |
| locations[0].source.host_organization_name | American Association for Clinical Chemistry |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320272 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://academic.oup.com/clinchem/article-pdf/67/12/1689/41387849/hvab187.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Clinical Chemistry |
| locations[0].landing_page_url | https://doi.org/10.1093/clinchem/hvab187 |
| locations[1].id | pmid:34643690 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Clinical chemistry |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/34643690 |
| locations[2].id | pmh:ru:oai:repository.ubn.ru.nl:2066/244656 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306401843 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Data Archiving and Networked Services (DANS) |
| locations[2].source.host_organization | https://openalex.org/I1322597698 |
| locations[2].source.host_organization_name | Royal Netherlands Academy of Arts and Sciences |
| locations[2].source.host_organization_lineage | https://openalex.org/I1322597698 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | info:eu-repo/semantics/article |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Clinical Chemistry, 67, 1689 - 1998 |
| locations[2].landing_page_url | http://hdl.handle.net/2066/244656 |
| locations[3].id | pmh:oai:repository.ubn.ru.nl:2066/244656 |
| locations[3].is_oa | False |
| locations[3].source.id | https://openalex.org/S4306401067 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Radboud Repository (Radboud University) |
| locations[3].source.host_organization | https://openalex.org/I145872427 |
| locations[3].source.host_organization_name | Radboud University Nijmegen |
| locations[3].source.host_organization_lineage | https://openalex.org/I145872427 |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Article / Letter to editor |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Clinical Chemistry, 67, 12, pp. 1689-1998 |
| locations[3].landing_page_url | https://repository.ubn.ru.nl/handle/2066/244656 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5020917234 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-4718-1764 |
| authorships[0].author.display_name | Pieter Langerhorst |
| authorships[0].countries | NL |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I145872427, https://openalex.org/I2802934949 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands |
| authorships[0].institutions[0].id | https://openalex.org/I2802934949 |
| authorships[0].institutions[0].ror | https://ror.org/05wg1m734 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I2802934949 |
| authorships[0].institutions[0].country_code | NL |
| authorships[0].institutions[0].display_name | Radboud University Medical Center |
| authorships[0].institutions[1].id | https://openalex.org/I145872427 |
| authorships[0].institutions[1].ror | https://ror.org/016xsfp80 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I145872427 |
| authorships[0].institutions[1].country_code | NL |
| authorships[0].institutions[1].display_name | Radboud University Nijmegen |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Pieter Langerhorst |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands |
| authorships[1].author.id | https://openalex.org/A5017563261 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-3776-2976 |
| authorships[1].author.display_name | Somayya Noori |
| authorships[1].countries | NL |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I2801952686 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands |
| authorships[1].institutions[0].id | https://openalex.org/I2801952686 |
| authorships[1].institutions[0].ror | https://ror.org/018906e22 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I2801952686 |
| authorships[1].institutions[0].country_code | NL |
| authorships[1].institutions[0].display_name | Erasmus MC |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Somayya Noori |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands |
| authorships[2].author.id | https://openalex.org/A5086904653 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-9874-2771 |
| authorships[2].author.display_name | Marina Zajec |
| authorships[2].countries | NL |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I2801952686 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands |
| authorships[2].affiliations[1].institution_ids | https://openalex.org/I2801952686 |
| authorships[2].affiliations[1].raw_affiliation_string | Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands |
| authorships[2].institutions[0].id | https://openalex.org/I2801952686 |
| authorships[2].institutions[0].ror | https://ror.org/018906e22 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I2801952686 |
| authorships[2].institutions[0].country_code | NL |
| authorships[2].institutions[0].display_name | Erasmus MC |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Marina Zajec |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands, Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands |
| authorships[3].author.id | https://openalex.org/A5047355338 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-7759-4968 |
| authorships[3].author.display_name | Yolanda B. de Rijke |
| authorships[3].countries | NL |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I2801952686 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands |
| authorships[3].institutions[0].id | https://openalex.org/I2801952686 |
| authorships[3].institutions[0].ror | https://ror.org/018906e22 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I2801952686 |
| authorships[3].institutions[0].country_code | NL |
| authorships[3].institutions[0].display_name | Erasmus MC |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Yolanda B De Rijke |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, the Netherlands |
| authorships[4].author.id | https://openalex.org/A5081336330 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-5976-8426 |
| authorships[4].author.display_name | Jolein Gloerich |
| authorships[4].countries | NL |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I145872427, https://openalex.org/I2802934949 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands |
| authorships[4].institutions[0].id | https://openalex.org/I2802934949 |
| authorships[4].institutions[0].ror | https://ror.org/05wg1m734 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I2802934949 |
| authorships[4].institutions[0].country_code | NL |
| authorships[4].institutions[0].display_name | Radboud University Medical Center |
| authorships[4].institutions[1].id | https://openalex.org/I145872427 |
| authorships[4].institutions[1].ror | https://ror.org/016xsfp80 |
| authorships[4].institutions[1].type | education |
| authorships[4].institutions[1].lineage | https://openalex.org/I145872427 |
| authorships[4].institutions[1].country_code | NL |
| authorships[4].institutions[1].display_name | Radboud University Nijmegen |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Jolein Gloerich |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands |
| authorships[5].author.id | https://openalex.org/A5003213355 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-0010-5286 |
| authorships[5].author.display_name | Alain J. van Gool |
| authorships[5].countries | NL |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I145872427, https://openalex.org/I2802934949 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands |
| authorships[5].institutions[0].id | https://openalex.org/I2802934949 |
| authorships[5].institutions[0].ror | https://ror.org/05wg1m734 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I2802934949 |
| authorships[5].institutions[0].country_code | NL |
| authorships[5].institutions[0].display_name | Radboud University Medical Center |
| authorships[5].institutions[1].id | https://openalex.org/I145872427 |
| authorships[5].institutions[1].ror | https://ror.org/016xsfp80 |
| authorships[5].institutions[1].type | education |
| authorships[5].institutions[1].lineage | https://openalex.org/I145872427 |
| authorships[5].institutions[1].country_code | NL |
| authorships[5].institutions[1].display_name | Radboud University Nijmegen |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Alain J van Gool |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands |
| authorships[6].author.id | https://openalex.org/A5023937847 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-9725-9323 |
| authorships[6].author.display_name | Hélène Caillon |
| authorships[6].countries | FR |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I3019204325 |
| authorships[6].affiliations[0].raw_affiliation_string | Laboratoire de Biochimie, Centre Hospitalier Universitaire (CHU), Nantes, France |
| authorships[6].institutions[0].id | https://openalex.org/I3019204325 |
| authorships[6].institutions[0].ror | https://ror.org/05c1qsg97 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I3019204325 |
| authorships[6].institutions[0].country_code | FR |
| authorships[6].institutions[0].display_name | Centre Hospitalier Universitaire de Nantes |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Hélène Caillon |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Laboratoire de Biochimie, Centre Hospitalier Universitaire (CHU), Nantes, France |
| authorships[7].author.id | https://openalex.org/A5052693979 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-2950-4977 |
| authorships[7].author.display_name | Irma Joosten |
| authorships[7].countries | NL |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I145872427, https://openalex.org/I2802934949 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands |
| authorships[7].institutions[0].id | https://openalex.org/I2802934949 |
| authorships[7].institutions[0].ror | https://ror.org/05wg1m734 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I2802934949 |
| authorships[7].institutions[0].country_code | NL |
| authorships[7].institutions[0].display_name | Radboud University Medical Center |
| authorships[7].institutions[1].id | https://openalex.org/I145872427 |
| authorships[7].institutions[1].ror | https://ror.org/016xsfp80 |
| authorships[7].institutions[1].type | education |
| authorships[7].institutions[1].lineage | https://openalex.org/I145872427 |
| authorships[7].institutions[1].country_code | NL |
| authorships[7].institutions[1].display_name | Radboud University Nijmegen |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Irma Joosten |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands |
| authorships[8].author.id | https://openalex.org/A5067643421 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-1962-561X |
| authorships[8].author.display_name | Theo M. Luider |
| authorships[8].countries | NL |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I2801952686 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands |
| authorships[8].institutions[0].id | https://openalex.org/I2801952686 |
| authorships[8].institutions[0].ror | https://ror.org/018906e22 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I2801952686 |
| authorships[8].institutions[0].country_code | NL |
| authorships[8].institutions[0].display_name | Erasmus MC |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Theo M Luider |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands |
| authorships[9].author.id | https://openalex.org/A5030565933 |
| authorships[9].author.orcid | https://orcid.org/0000-0003-1580-6106 |
| authorships[9].author.display_name | Jill Corre |
| authorships[9].countries | FR |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210098740 |
| authorships[9].affiliations[0].raw_affiliation_string | Unité de Génomique du Myélome, Institute Universitaire du Cancer de Toulouse Oncopole, Toulouse, France |
| authorships[9].institutions[0].id | https://openalex.org/I4210098740 |
| authorships[9].institutions[0].ror | https://ror.org/014hxhm89 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210098740 |
| authorships[9].institutions[0].country_code | FR |
| authorships[9].institutions[0].display_name | Institut universitaire du cancer de Toulouse Oncopole |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Jill Corre |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Unité de Génomique du Myélome, Institute Universitaire du Cancer de Toulouse Oncopole, Toulouse, France |
| authorships[10].author.id | https://openalex.org/A5045556768 |
| authorships[10].author.orcid | https://orcid.org/0000-0002-6654-994X |
| authorships[10].author.display_name | Martijn M. VanDuijn |
| authorships[10].countries | NL |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I2801952686 |
| authorships[10].affiliations[0].raw_affiliation_string | Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands |
| authorships[10].institutions[0].id | https://openalex.org/I2801952686 |
| authorships[10].institutions[0].ror | https://ror.org/018906e22 |
| authorships[10].institutions[0].type | healthcare |
| authorships[10].institutions[0].lineage | https://openalex.org/I2801952686 |
| authorships[10].institutions[0].country_code | NL |
| authorships[10].institutions[0].display_name | Erasmus MC |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Martijn M VanDuijn |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Department of Neurology, Erasmus University Medical Center, Rotterdam, the Netherlands |
| authorships[11].author.id | https://openalex.org/A5021139263 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-5080-6585 |
| authorships[11].author.display_name | Thomas Dejoie |
| authorships[11].countries | FR |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I3019204325 |
| authorships[11].affiliations[0].raw_affiliation_string | Laboratoire de Biochimie, Centre Hospitalier Universitaire (CHU), Nantes, France |
| authorships[11].institutions[0].id | https://openalex.org/I3019204325 |
| authorships[11].institutions[0].ror | https://ror.org/05c1qsg97 |
| authorships[11].institutions[0].type | healthcare |
| authorships[11].institutions[0].lineage | https://openalex.org/I3019204325 |
| authorships[11].institutions[0].country_code | FR |
| authorships[11].institutions[0].display_name | Centre Hospitalier Universitaire de Nantes |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Thomas Dejoie |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Laboratoire de Biochimie, Centre Hospitalier Universitaire (CHU), Nantes, France |
| authorships[12].author.id | https://openalex.org/A5042368190 |
| authorships[12].author.orcid | https://orcid.org/0000-0002-6208-6386 |
| authorships[12].author.display_name | Joannes F.M. Jacobs |
| authorships[12].countries | NL |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I145872427, https://openalex.org/I2802934949 |
| authorships[12].affiliations[0].raw_affiliation_string | Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands |
| authorships[12].institutions[0].id | https://openalex.org/I2802934949 |
| authorships[12].institutions[0].ror | https://ror.org/05wg1m734 |
| authorships[12].institutions[0].type | healthcare |
| authorships[12].institutions[0].lineage | https://openalex.org/I2802934949 |
| authorships[12].institutions[0].country_code | NL |
| authorships[12].institutions[0].display_name | Radboud University Medical Center |
| authorships[12].institutions[1].id | https://openalex.org/I145872427 |
| authorships[12].institutions[1].ror | https://ror.org/016xsfp80 |
| authorships[12].institutions[1].type | education |
| authorships[12].institutions[1].lineage | https://openalex.org/I145872427 |
| authorships[12].institutions[1].country_code | NL |
| authorships[12].institutions[1].display_name | Radboud University Nijmegen |
| authorships[12].author_position | last |
| authorships[12].raw_author_name | Joannes F M Jacobs |
| authorships[12].is_corresponding | True |
| authorships[12].raw_affiliation_strings | Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/clinchem/article-pdf/67/12/1689/41387849/hvab187.pdf |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10649 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2720 |
| primary_topic.subfield.display_name | Hematology |
| primary_topic.display_name | Multiple Myeloma Research and Treatments |
| related_works | https://openalex.org/W2062293155, https://openalex.org/W2013771509, https://openalex.org/W2347476677, https://openalex.org/W2810456981, https://openalex.org/W2118287225, https://openalex.org/W2742624826, https://openalex.org/W2009079013, https://openalex.org/W2182563913, https://openalex.org/W2411814702, https://openalex.org/W1557439734 |
| cited_by_count | 43 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 7 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 14 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 16 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 5 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 1 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1093/clinchem/hvab187 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S139212996 |
| best_oa_location.source.issn | 0009-9147, 1530-8561 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0009-9147 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Clinical Chemistry |
| best_oa_location.source.host_organization | https://openalex.org/P4310320272 |
| best_oa_location.source.host_organization_name | American Association for Clinical Chemistry |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320272 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://academic.oup.com/clinchem/article-pdf/67/12/1689/41387849/hvab187.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Clinical Chemistry |
| best_oa_location.landing_page_url | https://doi.org/10.1093/clinchem/hvab187 |
| primary_location.id | doi:10.1093/clinchem/hvab187 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S139212996 |
| primary_location.source.issn | 0009-9147, 1530-8561 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0009-9147 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Clinical Chemistry |
| primary_location.source.host_organization | https://openalex.org/P4310320272 |
| primary_location.source.host_organization_name | American Association for Clinical Chemistry |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320272 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://academic.oup.com/clinchem/article-pdf/67/12/1689/41387849/hvab187.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Clinical Chemistry |
| primary_location.landing_page_url | https://doi.org/10.1093/clinchem/hvab187 |
| publication_date | 2021-09-08 |
| publication_year | 2021 |
| referenced_works | https://openalex.org/W4252175385, https://openalex.org/W2025900814, https://openalex.org/W2032640560, https://openalex.org/W2999610272, https://openalex.org/W2999514175, https://openalex.org/W2486629951, https://openalex.org/W2780353907, https://openalex.org/W2134001103, https://openalex.org/W2893245372, https://openalex.org/W2925990378, https://openalex.org/W3111394247, https://openalex.org/W2025013606, https://openalex.org/W2165574508, https://openalex.org/W3004715879, https://openalex.org/W3128280427, https://openalex.org/W3016910448, https://openalex.org/W2604776612, https://openalex.org/W2728196933, https://openalex.org/W2153124929, https://openalex.org/W2089041106, https://openalex.org/W2730255373, https://openalex.org/W3041361317, https://openalex.org/W3135014753, https://openalex.org/W1994581694, https://openalex.org/W3049531330, https://openalex.org/W3101741724, https://openalex.org/W2786600572, https://openalex.org/W2980944048 |
| referenced_works_count | 28 |
| abstract_inverted_index.2 | 76 |
| abstract_inverted_index.a | 13, 32, 208 |
| abstract_inverted_index.(P | 194 |
| abstract_inverted_index.41 | 46, 82 |
| abstract_inverted_index.69 | 157 |
| abstract_inverted_index.81 | 125 |
| abstract_inverted_index.89 | 159 |
| abstract_inverted_index.In | 21, 80 |
| abstract_inverted_index.MM | 39, 47, 236 |
| abstract_inverted_index.an | 240 |
| abstract_inverted_index.as | 31 |
| abstract_inverted_index.at | 75 |
| abstract_inverted_index.in | 17, 49, 124, 175, 205, 231, 239 |
| abstract_inverted_index.is | 12, 98, 207, 237 |
| abstract_inverted_index.of | 45, 221, 225, 233 |
| abstract_inverted_index.on | 8, 59, 216 |
| abstract_inverted_index.or | 111, 147 |
| abstract_inverted_index.to | 37, 64, 87, 102, 106, 191, 213 |
| abstract_inverted_index.we | 24, 84 |
| abstract_inverted_index.(49 | 139 |
| abstract_inverted_index.(96 | 171 |
| abstract_inverted_index.50% | 133, 154, 169 |
| abstract_inverted_index.Our | 198 |
| abstract_inverted_index.PFS | 155, 170, 193 |
| abstract_inverted_index.The | 117, 132, 153, 167 |
| abstract_inverted_index.all | 81 |
| abstract_inverted_index.and | 62, 71, 92, 121, 158, 163, 227 |
| abstract_inverted_index.for | 141, 161, 180 |
| abstract_inverted_index.its | 228 |
| abstract_inverted_index.the | 50, 222 |
| abstract_inverted_index.was | 55, 130, 137, 156, 173, 188 |
| abstract_inverted_index.who | 143, 177 |
| abstract_inverted_index.79%. | 131 |
| abstract_inverted_index.able | 86 |
| abstract_inverted_index.bone | 9, 127, 217 |
| abstract_inverted_index.both | 181 |
| abstract_inverted_index.data | 199 |
| abstract_inverted_index.free | 113 |
| abstract_inverted_index.mass | 28 |
| abstract_inverted_index.more | 100 |
| abstract_inverted_index.poor | 192 |
| abstract_inverted_index.sera | 61 |
| abstract_inverted_index.that | 202 |
| abstract_inverted_index.this | 22 |
| abstract_inverted_index.time | 77 |
| abstract_inverted_index.were | 85, 144, 178 |
| abstract_inverted_index.with | 57, 235 |
| abstract_inverted_index.(MM). | 20 |
| abstract_inverted_index.(MRD) | 5 |
| abstract_inverted_index.(PFS) | 136 |
| abstract_inverted_index.after | 150 |
| abstract_inverted_index.blood | 206 |
| abstract_inverted_index.chain | 115 |
| abstract_inverted_index.light | 114 |
| abstract_inverted_index.major | 14 |
| abstract_inverted_index.serum | 112 |
| abstract_inverted_index.study | 23 |
| abstract_inverted_index.trial | 53 |
| abstract_inverted_index.value | 224, 230 |
| abstract_inverted_index.MS-MRD | 58, 95, 97, 122, 183, 203, 226 |
| abstract_inverted_index.detect | 103 |
| abstract_inverted_index.during | 185 |
| abstract_inverted_index.either | 107, 145 |
| abstract_inverted_index.frozen | 60 |
| abstract_inverted_index.larger | 242 |
| abstract_inverted_index.marrow | 10 |
| abstract_inverted_index.months | 160 |
| abstract_inverted_index.paired | 126 |
| abstract_inverted_index.status | 6, 123 |
| abstract_inverted_index.Methods | 42 |
| abstract_inverted_index.Minimal | 2 |
| abstract_inverted_index.NGS-MRD | 120, 214 |
| abstract_inverted_index.Results | 79 |
| abstract_inverted_index.Therapy | 43 |
| abstract_inverted_index.between | 119 |
| abstract_inverted_index.cohort. | 243 |
| abstract_inverted_index.disease | 4, 40 |
| abstract_inverted_index.longest | 168 |
| abstract_inverted_index.marrow. | 218 |
| abstract_inverted_index.measure | 38 |
| abstract_inverted_index.months) | 140, 172 |
| abstract_inverted_index.myeloma | 19 |
| abstract_inverted_index.patient | 210 |
| abstract_inverted_index.perform | 93 |
| abstract_inverted_index.points. | 78 |
| abstract_inverted_index.protein | 68 |
| abstract_inverted_index.relapse | 184 |
| abstract_inverted_index.routine | 65 |
| abstract_inverted_index.samples | 129 |
| abstract_inverted_index.&lt; | 195 |
| abstract_inverted_index.(MS-MRD) | 30 |
| abstract_inverted_index.0.0001). | 196 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Clinical | 219 |
| abstract_inverted_index.IFM-2009 | 51 |
| abstract_inverted_index.assessed | 7, 56, 215 |
| abstract_inverted_index.clinical | 52 |
| abstract_inverted_index.compared | 63, 105 |
| abstract_inverted_index.directly | 149 |
| abstract_inverted_index.friendly | 211 |
| abstract_inverted_index.identify | 88 |
| abstract_inverted_index.indicate | 200 |
| abstract_inverted_index.invasive | 35 |
| abstract_inverted_index.methods. | 182 |
| abstract_inverted_index.multiple | 18 |
| abstract_inverted_index.observed | 174 |
| abstract_inverted_index.patients | 48, 83, 142, 176, 234 |
| abstract_inverted_index.peptides | 91 |
| abstract_inverted_index.residual | 3 |
| abstract_inverted_index.response | 44 |
| abstract_inverted_index.survival | 135 |
| abstract_inverted_index.targeted | 27 |
| abstract_inverted_index.(NGS-MRD) | 74 |
| abstract_inverted_index.M-protein | 104, 109 |
| abstract_inverted_index.activity. | 41 |
| abstract_inverted_index.analysis. | 116 |
| abstract_inverted_index.aspirates | 11 |
| abstract_inverted_index.biomarker | 16 |
| abstract_inverted_index.evaluated | 25 |
| abstract_inverted_index.feasible, | 209 |
| abstract_inverted_index.identical | 138 |
| abstract_inverted_index.minimally | 34 |
| abstract_inverted_index.patients, | 165 |
| abstract_inverted_index.sensitive | 101 |
| abstract_inverted_index.treatment | 187 |
| abstract_inverted_index.warranted | 238 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.clonotypic | 89 |
| abstract_inverted_index.correlated | 190 |
| abstract_inverted_index.evaluation | 204 |
| abstract_inverted_index.monoclonal | 67 |
| abstract_inverted_index.prognostic | 15, 223 |
| abstract_inverted_index.sensitive, | 33 |
| abstract_inverted_index.sequencing | 73 |
| abstract_inverted_index.treatment. | 152 |
| abstract_inverted_index.validation | 220 |
| abstract_inverted_index.(M-protein) | 69 |
| abstract_inverted_index.Conclusions | 197 |
| abstract_inverted_index.MS-negative | 164 |
| abstract_inverted_index.MS-positive | 148 |
| abstract_inverted_index.alternative | 36, 212 |
| abstract_inverted_index.blood-based | 26 |
| abstract_inverted_index.concordance | 118 |
| abstract_inverted_index.diagnostics | 70, 110 |
| abstract_inverted_index.independent | 241 |
| abstract_inverted_index.maintenance | 151, 186 |
| abstract_inverted_index.marrow/sera | 128 |
| abstract_inverted_index.serum-based | 94 |
| abstract_inverted_index.MRD-negative | 179 |
| abstract_inverted_index.NGS-negative | 162 |
| abstract_inverted_index.NGS-positive | 146 |
| abstract_inverted_index.spectrometry | 29 |
| abstract_inverted_index.(NCT01191060) | 54 |
| abstract_inverted_index.complementary | 229 |
| abstract_inverted_index.measurements. | 96 |
| abstract_inverted_index.respectively. | 166 |
| abstract_inverted_index.significantly | 99, 189 |
| abstract_inverted_index.MRD-evaluation | 232 |
| abstract_inverted_index.electrophoretic | 108 |
| abstract_inverted_index.next-generation | 72 |
| abstract_inverted_index.progression-free | 134 |
| abstract_inverted_index.state-of-the-art | 66 |
| abstract_inverted_index.M-protein-specific | 90 |
| abstract_inverted_index.proof-of-principle | 201 |
| cited_by_percentile_year.max | 100 |
| cited_by_percentile_year.min | 89 |
| corresponding_author_ids | https://openalex.org/A5042368190 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 13 |
| corresponding_institution_ids | https://openalex.org/I145872427, https://openalex.org/I2802934949 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/1 |
| sustainable_development_goals[0].score | 0.4699999988079071 |
| sustainable_development_goals[0].display_name | No poverty |
| citation_normalized_percentile.value | 0.96554243 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |